Daniel Khalaf

2.3k total citations · 1 hit paper
41 papers, 1.2k citations indexed

About

Daniel Khalaf is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel Khalaf has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 17 papers in Cancer Research and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel Khalaf's work include Prostate Cancer Treatment and Research (27 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Cancer Genomics and Diagnostics (12 papers). Daniel Khalaf is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Cancer Genomics and Diagnostics (12 papers). Daniel Khalaf collaborates with scholars based in Canada, Finland and Australia. Daniel Khalaf's co-authors include Kim N., Martin Gleave, Alexander W. Wyatt, Matti Annala, Daygen L. Finch, Muhammad Zulfiqar, Joanna Vergidis, Kevin Beja, Gillian Vandekerkhove and Bernhard J. Eigl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Daniel Khalaf

38 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

2018 347 citations Matti Annala, Gillian Vandekerkhove et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Khalaf Canada	12	1.1k	590	411	300	234	41	1.2k
Joanna Vergidis Canada	12	772 0.7×	386 0.7×	334 0.8×	215 0.7×	201 0.9×	27	980
Evan W. Warner Canada	10	1.0k 1.0×	672 1.1×	388 0.9×	342 1.1×	136 0.6×	19	1.2k
S. Chowdhury United Kingdom	16	699 0.6×	291 0.5×	267 0.6×	290 1.0×	242 1.0×	58	951
Katherine Sunderland Canada	10	694 0.6×	331 0.6×	230 0.6×	161 0.5×	190 0.8×	23	761
Franck Priou France	10	624 0.6×	239 0.4×	246 0.6×	188 0.6×	157 0.7×	25	760
Per Rathenborg Denmark	11	923 0.9×	325 0.6×	309 0.8×	204 0.7×	308 1.3×	18	1.1k
Eren Demirhan United States	8	678 0.6×	231 0.4×	290 0.7×	201 0.7×	219 0.9×	15	955
Kris Deprince United States	7	948 0.9×	312 0.5×	252 0.6×	168 0.6×	333 1.4×	15	1.2k
Giorgia Gurioli Italy	17	476 0.4×	426 0.7×	217 0.5×	399 1.3×	97 0.4×	68	913
Vahid Naini United States	8	1.1k 1.0×	357 0.6×	244 0.6×	138 0.5×	417 1.8×	21	1.2k

Countries citing papers authored by Daniel Khalaf

Since Specialization

Citations

This map shows the geographic impact of Daniel Khalaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Khalaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Khalaf more than expected).

Fields of papers citing papers by Daniel Khalaf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Khalaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Khalaf. The network helps show where Daniel Khalaf may publish in the future.

Co-authorship network of co-authors of Daniel Khalaf

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Khalaf. A scholar is included among the top collaborators of Daniel Khalaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Khalaf. Daniel Khalaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bacon, Jack V. W., Cameron Herberts, Cecily Q. Bernales, et al.. (2025). Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma. npj Precision Oncology. 9(1). 177–177. 1 indexed citations

Lavoie, Jean‐Michel, Elizabeth A. Chavez, Lucia Nappi, et al.. (2022). Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. Frontiers in Oncology. 12. 973402–973402. 3 indexed citations

Annala, Matti, Sinja Taavitsainen, Daniel Khalaf, et al.. (2021). Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research. 27(16). 4610–4623. 52 indexed citations

Warner, Evan W., Cameron Herberts, Simon Fu, et al.. (2021). BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research. 27(6). 1650–1662. 52 indexed citations

Soleimani, Maryam, Katherine Sunderland, Werner J. Struss, et al.. (2021). Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study. European Journal of Cancer. 152. 215–222. 11 indexed citations

N., Kim, et al.. (2021). Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. Translational Andrology and Urology. 10(10). 3931–3945. 9 indexed citations

Saxena, Neetu, et al.. (2021). 693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy. Annals of Oncology. 32. S708–S708. 2 indexed citations

Warner, Evan W., Steven Yip, Matti Annala, et al.. (2020). Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations. Clinical Cancer Research. 26(11_Supplement). PR09–PR09. 1 indexed citations

Khalaf, Daniel, Matti Annala, Sinja Taavitsainen, et al.. (2019). Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. The Lancet Oncology. 20(12). 1730–1739. 213 indexed citations

10.

Lavoie, Jean‐Michel, Gillian Vandekerkhove, Matti Annala, et al.. (2019). Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC). Annals of Oncology. 30. v376–v376.

11.

Tinker, Anna V., Peter Lim, Christina Aquino‐Parsons, et al.. (2019). Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.. Journal of Clinical Oncology. 37(15_suppl). TPS5604–TPS5604. 1 indexed citations

12.

Vandekerkhove, Gillian, Werner J. Struss, Matti Annala, et al.. (2019). Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology. 75(4). 667–675. 134 indexed citations

13.

Annala, Matti, Gillian Vandekerkhove, Daniel Khalaf, et al.. (2018). Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery. 8(4). 444–457. 347 indexed citations breakdown →

14.

Khalaf, Daniel, Katherine Sunderland, Bernhard J. Eigl, et al.. (2018). Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. European Urology. 75(6). 940–947. 58 indexed citations

15.

Lavoie, Jean‐Michel, Daniel Khalaf, Bernhard J. Eigl, et al.. (2018). Clinical effectiveness of docetaxel for castration‐sensitive prostate cancer in a real‐world population‐based analysis. The Prostate. 79(3). 281–287. 16 indexed citations

16.

Lavoie, Jean‐Michel, Daniel Khalaf, Bernhard J. Eigl, et al.. (2018). Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis.. Journal of Clinical Oncology. 36(6_suppl). 297–297. 1 indexed citations

17.

Annala, Matti, Werner J. Struss, Evan W. Warner, et al.. (2017). Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer. European Urology. 72(1). 34–42. 169 indexed citations

18.

Khalaf, Daniel, Arun Azad, Katherine Sunderland, et al.. (2017). A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Canadian Urological Association Journal. 12(2). E47–52. 10 indexed citations

19.

Villarreal‐Garza, Cynthia, Daniel Khalaf, Nathaniel Bouganim, et al.. (2014). Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Research and Treatment. 146(3). 567–572. 26 indexed citations

20.

Khalaf, Daniel, John Hilton, Mark Clemons, et al.. (2014). Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncology Letters. 7(3). 866–870. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact